{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:37:26Z","timestamp":1761514646190,"version":"3.41.2"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.576624","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T15:14:49Z","timestamp":1600442089000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Laura","family":"Micheli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Di Cesare Mannelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Lucarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Parisio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Toti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Adele","family":"Rigamonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Calosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Ghelardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1)","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med."},{"key":"B2","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"B3","first-page":"193","article-title":"Physiology and pharmacology of vomiting","volume":"5","author":"Borison","year":"1953","journal-title":"Pharmacol. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.2165\/11634970-000000000-00000","article-title":"Opioid-induced bowel dysfunction: pathophysiology and management","volume":"72","author":"Brock","year":"2012","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pain.2003.09.011","article-title":"Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects","volume":"107","author":"Cepeda","year":"2004","journal-title":"Pain"},{"key":"B6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0006-8993(02)02268-0","article-title":"Excitotoxic neurodegeneration induced by intranasal administration of kainic acid in C57BL\/6 mice","volume":"931","author":"Chen","year":"2002","journal-title":"Brain Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0376-8716(95)01153-p","article-title":"Assessment of nalmefene glucuronide as a selective gut opioid antagonist","volume":"39","author":"Cheskin","year":"1995","journal-title":"Drug Alcohol Depend."},{"key":"B8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1358\/dot.2015.51.8.2364896","article-title":"Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation","volume":"51","author":"Corsetti","year":"2015","journal-title":"Drugs Today (Barc.)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1517\/14656566.2015.991306","article-title":"Naloxegol, a new drug for the treatment of opioid-induced constipation","volume":"16","author":"Corsetti","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0304-3959(99)00223-7","article-title":"Antagonists of excitatory opioid receptor functions enhance morphine\u2019s analgesic potency and attenuate opioid tolerance\/dependence liability","volume":"84","author":"Crain","year":"2000","journal-title":"Pain"},{"key":"B11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/clpt.1992.106","article-title":"Treatment of opioid-induced constipation with oral naloxone: a pilot study","volume":"52","author":"Culpepper-Morgan","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0163-7258(95)02053-5","article-title":"Insights into opioid action in the intestinal tract","volume":"69","author":"De Luca","year":"1996","journal-title":"Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.bbamem.2008.09.016","article-title":"Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery","volume":"1788","author":"Deli","year":"2009","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0378-5173(03)00039-5","article-title":"Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats","volume":"255","author":"Dufes","year":"2003","journal-title":"Int. J. Pharm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.pbb.2003.09.014","article-title":"Hypericum perforatum extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnestic dose of scopolamine","volume":"76","author":"El-Sherbiny","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-1050-2_3","article-title":"Tissue processing and hematoxylin and eosin staining","volume":"1180","author":"Feldman","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2165\/00003495-198835030-00002","article-title":"Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence","volume":"35","author":"Gonzalez","year":"1988","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1097\/AJP.0b013e31816b58eb","article-title":"Management of expected and unexpected opioid-related side effects","volume":"24","author":"Harris","year":"2008","journal-title":"Clin. J. Pain"},{"key":"B19","first-page":"81","article-title":"Vivitrex (Alkermes\/Cephalon)","volume":"7","author":"Heading","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2466\/pr0.1967.21.1.221","article-title":"An improved one-trial passive avoidance learning situation","volume":"21","author":"Jarvik","year":"1967","journal-title":"Psychol. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e13563","DOI":"10.1111\/nmo.13563","article-title":"Pharmacologic effects of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation","volume":"31","author":"Kanemasa","year":"2019","journal-title":"Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc."},{"key":"B22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1254\/jjp.27.117","article-title":"Effects of central depressants on rota-rod and traction performances in mice","volume":"27","author":"Kuribara","year":"1977","journal-title":"Jpn. J. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.jaad.2018.12.031","article-title":"The uses of naltrexone in dermatologic conditions","volume":"80","author":"Lee","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s005200050111","article-title":"Opioids: overview on action, interaction and toxicity","volume":"5","author":"Lehmann","year":"1997","journal-title":"Support Care Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0885-3924(01)00369-4","article-title":"Low-dose oral naloxone reverses opioid-induced constipation and analgesia","volume":"23","author":"Liu","year":"2002","journal-title":"J. Pain Symptom Manage."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.xphs.2015.12.016","article-title":"Development and evaluation of a novel intranasal spray for the delivery of amantadine","volume":"105","author":"Lungare","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/10550490050173181","article-title":"Substance dependence and other psychiatric disorders among drug dependent subjects: race and gender correlates","volume":"9","author":"M. Compton","year":"2000","journal-title":"Am. J. Addict."},{"key":"B28","first-page":"RR-2108-QSD","article-title":"Effects of Medication-Assisted Treatment (MAT) for opioid use disorder on functional outcomes: a systematic review","volume":"8","author":"Maglione","year":"2020","journal-title":"Rand Heal. Q."},{"key":"B29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.36076\/ppj.2004\/7\/431","article-title":"Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: a prospective, observational study","volume":"7","author":"Manchikanti","year":"2004","journal-title":"Pain Physician"},{"key":"B30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.36076\/ppj.2005\/8\/335","article-title":"Evolution of the National All Schedules Prescription Electronic Reporting Act (NASPER): a public law for balancing treatment of pain and drug abuse and diversion","volume":"8","author":"Manchikanti","year":"2005","journal-title":"Pain Physician"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1111\/bph.12955","article-title":"Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP","volume":"172","author":"McGrath","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0031-9384(76)90171-2","article-title":"Poison induced pica in rats","volume":"17","author":"Mitchell","year":"1976","journal-title":"Physiol. Behav."},{"key":"B33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0031-9384(77)90103-2","article-title":"Pica: A species relevant behavioral assay of motion sickness in the rat","volume":"18","author":"Mitchell","year":"1977","journal-title":"Physiol. Behav."},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/00003495-200363010-00002","article-title":"Responsible prescribing of opioids for the management of chronic pain","volume":"63","author":"Nicholson","year":"2003","journal-title":"Drugs"},{"key":"B35","first-page":"497","article-title":"Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure","volume":"192","author":"O\u2019Callaghan","year":"1975","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0002-9610(01)00782-6","article-title":"Incidence, prevalence, and management of opioid bowel dysfunction","volume":"182","author":"Pappagallo","year":"2001","journal-title":"Am. J. Surg."},{"key":"B37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0885-3924(95)00187-5","article-title":"Opioid therapy for chronic nonmalignant pain: a review of the critical issues","volume":"11","author":"Portenoy","year":"1996","journal-title":"J. Pain Symptom Manage."},{"key":"B38","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/0196-9781(88)90141-6","article-title":"The action of FMRFamide (Phe-Met-Arg-Phe-NH2) and related peptides on mammals","volume":"9","author":"Raffa","year":"1988","journal-title":"Peptides"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/pme.12704","article-title":"Low-dose naltrexone to prevent intolerable morphine adverse events: a forgotten remedy for a neglected, global clinical need","volume":"16","author":"Raffaeli","year":"2015","journal-title":"Pain Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF00501390","article-title":"Centrally and peripherally mediated inhibition of intestinal motility by opioids","volume":"308","author":"Schulz","year":"1979","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"B41","first-page":"492","article-title":"Peptide opioid antagonist separates peripheral and central opioid antitransit effects","volume":"243","author":"Shook","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3109\/J427v01n01_03","article-title":"A receptor-based paradigm of nausea and vomiting","volume":"1","author":"Smith","year":"2005","journal-title":"J. Cancer Pain Symptom Palliation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s13181-015-0512-x","article-title":"Naltrexone: Not just for opioids anymore","volume":"12","author":"Sudakin","year":"2016","journal-title":"J. Med. Toxicol."},{"key":"B44","first-page":"1347","article-title":"Management of common opioid-induced adverse effects","volume":"74","author":"Swegle","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"B45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0272-7358(99)00026-4","article-title":"The comorbidity of depression and substance use disorders","volume":"20","author":"Swendsen","year":"2000","journal-title":"Clin. Psychol. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/01.PCC.0000216421.72002.09","article-title":"The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit","volume":"7","author":"Tofil","year":"2006","journal-title":"Pediatr. Crit. Care Med."},{"key":"B47","first-page":"1","article-title":"Opioid guidelines in the management of chronic non-cancer pain","volume":"9","author":"Trescot","year":"2006","journal-title":"Pain Physician"},{"key":"B48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/J354v21n01_05","article-title":"Adverse effects of opioids on the central nervous systems of palliative care patients","volume":"21","author":"Vella-Brincat","year":"2007","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jpainsymman.2010.05.004","article-title":"Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and Sequestered Naltrexone, in Patients with Chronic, Moderate to Severe Pain","volume":"40","author":"Webster","year":"2010","journal-title":"J. Pain Symptom Manage."},{"key":"B50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ejpb.2009.08.008","article-title":"RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies","volume":"74","author":"Wengst","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00418-008-0410-2","article-title":"Epithelial and endothelial barriers in the olfactory region of the nasal cavity of the rat","volume":"130","author":"Wolburg","year":"2008","journal-title":"Histochem. Cell Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1743-3150.2004.00554.x","article-title":"Function of opioids in the enteric nervous system","volume":"16","author":"Wood","year":"2004","journal-title":"Neurogastroenterol. Motil."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.576624\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T11:36:58Z","timestamp":1617363418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.576624\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":52,"alternative-id":["10.3389\/fphar.2020.576624"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.576624","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"article-number":"576624"}}